Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: A prospective evaluation in a consecutive series of 210 cases

Scandinavian Journal of Urology and Nephrology

Volumn 42, Issue 6, 2008, Pages 522-527

  Engeler, Daniel S ^a   Wyler, Stephen ^a   Neyer, Michael ^a   Hobi, Christian ^a   Müller, Jürg ^a   Schmid, Hans Peter ^a  

^a Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

Author keywords

Adjuvant chemotherapy; Bladder neoplasms; Epirubicin; Intravesical administration

Indexed keywords

EPIRUBICIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; CYSTECTOMY; CYSTOSCOPY; DECISION MAKING; DRUG INSTILLATION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PAPILLARY CARCINOMA; PERFORATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BIOPSY; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; CYSTOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INSTILLATION, DRUG; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 49349116181     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590802133099     Document Type: Article

References (9)

1. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90.
2. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995;153:934-41.
3. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stöckle M, Sternberg C. Guidelines on bladder cancer. Eur Urol 2002;41:105-12.
4. Dawkins GP, Miller RA. Sorbitol-mannitol solution for urological electrosurgical resection - a safer fluid than glycine 1.5%. Eur Urol 1999;36:99-102.
5. Witjes JA, Melissen DO, Kiemeney LA. Current practice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. Eur Urol 2006;49:478-84.
6. Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, et al. Randomized study of single early instillation of (2″R)-4′-O- tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002;94:2363-8.
7. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 2006;175:2004-10.
8. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 1993;149:749-52.
9. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999;161:1120-3.